Interferon is the first line of innate defense against viruses infection. Interferon a1b is a major antiviral subtype of interferon family. SARS-CoV-2 have evolved several mechanisms to block interferon induction. Interferon α1b, has been approved for the antiviral clin. use for many years, showing strong in-vitro antiviral activity against SARS-CoV-2. Preliminary clin. studies including type I interferon have showed critical pos. efficiency on COVID-19 treatment and prevention. A clin. trial with a larger cohort of infected patients that are randomized to treatment with interferon-alpha or to a placebo is ongoing.